Global Dexlansoprazole Sustained Release Capsule Market Growth 2025-2031
Description
The global Dexlansoprazole Sustained Release Capsule market size is predicted to grow from US$ 337 million in 2025 to US$ 465 million in 2031; it is expected to grow at a CAGR of 5.5% from 2025 to 2031.
Dexlansoprazole sustained-release capsules were approved by the U.S. FDA in January 2009, under the trade name DEXILANT. For the treatment of heartburn caused by non-erosive gastroesophageal reflux disease (GERD), erosive esophagitis (EE) and maintenance treatment after healing of erosive esophagitis, all of which are administered once a day.
United States market for Dexlansoprazole Sustained Release Capsule is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Dexlansoprazole Sustained Release Capsule is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Dexlansoprazole Sustained Release Capsule is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Dexlansoprazole Sustained Release Capsule players cover TAKEDA PHARM, PAR PHARM, TWI PHARM, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Dexlansoprazole Sustained Release Capsule Industry Forecast” looks at past sales and reviews total world Dexlansoprazole Sustained Release Capsule sales in 2024, providing a comprehensive analysis by region and market sector of projected Dexlansoprazole Sustained Release Capsule sales for 2025 through 2031. With Dexlansoprazole Sustained Release Capsule sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Dexlansoprazole Sustained Release Capsule industry.
This Insight Report provides a comprehensive analysis of the global Dexlansoprazole Sustained Release Capsule landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Dexlansoprazole Sustained Release Capsule portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Dexlansoprazole Sustained Release Capsule market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Dexlansoprazole Sustained Release Capsule and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Dexlansoprazole Sustained Release Capsule.
This report presents a comprehensive overview, market shares, and growth opportunities of Dexlansoprazole Sustained Release Capsule market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
30MG
60MG
Segmentation by Application:
Hospital
Clinic
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
TAKEDA PHARM
PAR PHARM
TWI PHARM
Key Questions Addressed in this Report
What is the 10-year outlook for the global Dexlansoprazole Sustained Release Capsule market?
What factors are driving Dexlansoprazole Sustained Release Capsule market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Dexlansoprazole Sustained Release Capsule market opportunities vary by end market size?
How does Dexlansoprazole Sustained Release Capsule break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Dexlansoprazole sustained-release capsules were approved by the U.S. FDA in January 2009, under the trade name DEXILANT. For the treatment of heartburn caused by non-erosive gastroesophageal reflux disease (GERD), erosive esophagitis (EE) and maintenance treatment after healing of erosive esophagitis, all of which are administered once a day.
United States market for Dexlansoprazole Sustained Release Capsule is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Dexlansoprazole Sustained Release Capsule is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Dexlansoprazole Sustained Release Capsule is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Dexlansoprazole Sustained Release Capsule players cover TAKEDA PHARM, PAR PHARM, TWI PHARM, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Dexlansoprazole Sustained Release Capsule Industry Forecast” looks at past sales and reviews total world Dexlansoprazole Sustained Release Capsule sales in 2024, providing a comprehensive analysis by region and market sector of projected Dexlansoprazole Sustained Release Capsule sales for 2025 through 2031. With Dexlansoprazole Sustained Release Capsule sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Dexlansoprazole Sustained Release Capsule industry.
This Insight Report provides a comprehensive analysis of the global Dexlansoprazole Sustained Release Capsule landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Dexlansoprazole Sustained Release Capsule portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Dexlansoprazole Sustained Release Capsule market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Dexlansoprazole Sustained Release Capsule and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Dexlansoprazole Sustained Release Capsule.
This report presents a comprehensive overview, market shares, and growth opportunities of Dexlansoprazole Sustained Release Capsule market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
30MG
60MG
Segmentation by Application:
Hospital
Clinic
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
TAKEDA PHARM
PAR PHARM
TWI PHARM
Key Questions Addressed in this Report
What is the 10-year outlook for the global Dexlansoprazole Sustained Release Capsule market?
What factors are driving Dexlansoprazole Sustained Release Capsule market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Dexlansoprazole Sustained Release Capsule market opportunities vary by end market size?
How does Dexlansoprazole Sustained Release Capsule break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
76 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Dexlansoprazole Sustained Release Capsule by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Dexlansoprazole Sustained Release Capsule by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
